Trial Profile

KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KB 407 (Primary)
Indications Cystic fibrosis
Focus Adverse reactions
Acronyms CORAL-1
Sponsors Krystal Biotech

Most Recent Events

21 Aug 2025 Planned End Date changed from 1 Jul 2025 to 1 Jun 2026.
21 Aug 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2025.
04 Aug 2025 According to a Krystal Biotech media release, company expects to provide an interim molecular data readout for Cohort 3 patients before year end. Till date Company has enrolled 4 patients in Cohort 3 of CORAL-1.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com